Ballentine Partners’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$496K Buy
6,331
+69
+1% +$4.71K 0.01% 571
2026
Q1
$405K Hold
6,262
0.01% 602
2025
Q4
$421K Sell
6,262
-315
-5% -$21.2K 0.01% 576
2025
Q3
$482K Sell
6,577
-48
-0.7% -$3.19K 0.01% 518
2025
Q2
$345K Sell
6,625
-19
-0.3% -$1.08K 0.01% 627
2025
Q1
$424K Buy
6,644
+160
+2% +$9.29K 0.01% 501
2024
Q4
$310K Buy
6,484
+46
+0.7% +$2.36K 0.01% 590
2024
Q3
$369K Buy
6,438
+19
+0.3% +$1.09K 0.01% 515
2024
Q2
$336K Buy
6,419
+129
+2% +$5.66K 0.01% 524
2024
Q1
$256K Sell
6,290
-100
-2% -$3.75K ﹤0.01% 595
2023
Q4
$236K Buy
6,390
+145
+2% +$5.46K ﹤0.01% 581
2023
Q3
$239K Buy
6,245
+89
+1% +$3.65K 0.01% 499
2023
Q2
$222K Buy
+6,156
New +$210K 0.01% 524

Other funds holding HALO

Ballentine Partners's HALO Position: Q2 2026 in Review

Ballentine Partners increased its Halozyme (HALO) stake by 1.1% in Q2 2026, buying an estimated $4.71K and bringing the position to 6,331 shares worth $496K. The position accounts for 0.01% of the portfolio, ranked #571.

Ballentine Partners first reported a position in HALO in Q2 2023 and has held it in 13 quarters since. 106 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Ballentine Partners held 6,331 shares of Halozyme worth $496K as of Q2 2026.
  • Ballentine Partners bought 69 Halozyme shares in Q2 2026, an estimated $4.71K.
  • Halozyme made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #571 holding.
  • Ballentine Partners first reported a position in Halozyme in Q2 2023 and has held it in 13 quarters since.
  • 106 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.